Background: The prevalence of lower extremity artery disease (LEAD) is high (20%-25%) in the population older than 65 years, but patients are seldom identified until the disease is advanced. Circulating markers of disease activity might provide patients with a key opportunity for timely treatment. We tested the hypothesis that measuring blood-specific fragments generated during degradation of the extracellular matrix (ECM) could provide further insight into the pathophysiologic mechanism of arterial remodeling.
Atherosclerosis is a progressive, age-related disease that may simultaneously affect multiple arteries. The interest in noncoronary atherosclerosis is increasing because patients with manifestations in several vascular beds have poorer prognosis than those with just one territory affected. 1 This association is particularly evident in patients with lower extremity artery disease (LEAD; also known as peripheral artery disease, PAD). There are >200 million patients with LEAD in industrialized countries, and the convergent epidemics of diabetes and obesity suggest bleak prospects. 1, 2 Despite its major prognostic impact, limited information is available on asymptomatic PAD. The life expectancy of a patient with either intermittent claudication (IC) or critical limb ischemia (CLI) is low, and once diagnosed, patients have significantly less chance of receiving risk factor modification than patients with coronary disease. 3, 4 The challenge is to establish whether lesions in lower extremity arterial occlusive disease have a specific proteome and to propose noninvasive surrogates to anticipate prevention strategies. Locoregional hemodynamic and rheologic factors favor the progression of atherosclerotic lesions in lower extremity arteries, and reduction in lumen caliber governs the course of symptoms in patients with LEAD. 5 Vessel wall remodeling and angiogenesis in peripheral arteries appear to be crucial processes to understanding of the overall response to atherosclerotic injuries. 6 In this scenario, the extracellular matrix (ECM) provides a mechanical scaffold and support to cell migration, which is regulated by the correct functioning of cytokines, enzymes such as matrix metalloproteinases (MMPs), and growth factors. [7] [8] [9] Atherosclerosis-associated remodeling and disrupted cytoskeletal architecture are the consequence of inflammatory cell activity, lipid deposition, and changes in ECM balance. [10] [11] [12] [13] [14] We address the proteome composition and the relative expression of ECM components in severely affected peripheral arteries to evaluate different neoepitope biomarkers of ECM degradation measured in serum from PAD patients to assess whether these markers might be associated with disease activity.
METHODS
Participants and study design. The local Ethics Committee and Institutional Review Board approved the procedures involved in this study (Epinols/12-03-09/3proj6; Inflamet/15-04-30/4proj6). First, histologic and proteomic analyses were performed in portions of superficial femoral arteries that included the entire artery wall from patients requiring infrainguinal limb revascularization (n ¼ 18) and controls (n ¼ 3) obtained from road accident victims of similar age. Written informed consent was obtained from participants or next of kin. Demographic and cardiovascular risk profiles of control individuals and PAD patients used for these analyses can be found in the Supplementary Methods and Supplementary Table I (online only). To limit likely sex differences and because the disease is more prevalent in men, we then recruited men with an established diagnosis of PAD attending our Department of Vascular Surgery. There were 195 participants included. Serum was collected at the time of inclusion, identified according to Fontaine classification, 15 and stored at À80 C until analyses. Exclusion criteria were clinically assessed; patients with infected lesions, evidence of recent neoplastic disease, chronic kidney disease, liver disease, or inflammatory disease (or receiving anti-inflammatory drugs) were excluded. Ankle-brachial index (ABI) was measured per standard technique in both lower limbs, and imaging techniques were performed according to the standard of care.
Histologic examination. To examine tissue morphologic features, serial sections of tissue were obtained from samples fixed in 10% neutral buffered formalin and embedded in paraffin. Hematoxylin and eosin staining (Sigma-Aldrich, Steinheim, Germany) was used to identify different cellular structures. Masson trichrome staining (Bio Optica, Milan, Italy) was used to assess collagen fibers, smooth muscle cells, nucleus, and cytoplasm, and sirius red staining (direct red 80; SigmaAldrich) was used to identify collagen fibers. Images were obtained at 200Â magnification, and the intimamedia ratio was obtained by dividing the thickness of the intima by the thickness of the media measured using an optical microscope (Eclipse E600; Nikon, Madrid, Spain) equipped with image analysis.
Untargeted proteomics. To explore the proteome composition of the arteries, we used a nondirected proteomic approach. Proteomics experiments were exploratory, with extensive mapping of digested peptides to identify and to quantify as many proteins as possible, and performed using chemical labeling to differentiate groups. Methods were similar to those previously used to analyze the protein secretion profile of carotid atherosclerotic plaques. 16 Specific details may be found in the Supplementary Methods (online only). Briefly, sample arteries were cut into pieces and homogenized in the presence of type 1 collagenase (Sigma-Aldrich). Following different rounds of centrifugation and chemical treatment, precipitated proteins were vacuum dried and dissolved. Samples were then sequentially denatured, reduced, and alkylated. For digestion, samples were incubated with sequencing-grade trypsin overnight at 37 C. We used a liquid chromatography-mass spectrometry (MS) approach for quantification by performing isobaric tag for relative and absolute quantitation (iTRAQ) labeling with iTRAQ 8-plex reagent kits (SCIEX, Madrid, Spain), as previously described. 17 Only proteins that appeared in >70% of the samples were considered, and the PANTHER system (www.pantherdb. org) was used for functional classification. We used the Benjamini-Hochberg method to avoid false positives in differences due to multiple testing. Analyses with receiver operating characteristic curves, linear regression, and binary logistic regression were performed using the Statistical Package for the Social Sciences, version 22.0 (IBM Corp, Armonk, NY). MetaboAnalyst 3.0 (http://www. metaboanalyst.ca/) was used to generate scores/loading plots, heatmaps, and random forest analysis.
RESULTS
We first evaluated, combining histology and untargeted proteomics, the differences in the integrity of arterial tissue and signs of vascular remodeling, in severely lesioned and healthy arteries, to confirm that samples from PAD patients were representative of the pathologic state. Atherosclerosis was evident in all samples from PAD patients ( Supplementary Fig, online only) . To mitigate run-to-run variability, we quantified samples that have been multiplexed, covalently labeled, and then combined in a single run containing multiple samples. Peptides present in <70% of the samples in both control and PAD arteries and those generating similar fingerprint spectra were not considered in further data-dependent analyses (Supplementary Table III , online only). Under these conditions, this proteomics approach selected 81 proteins, and quantitative analysis revealed a unique subset of 14 proteins with statistically significant differences between diseased and healthy arteries (Fig 1, A) . Their putative functions in atherosclerosis (Supplementary Table III , online only) disclosed that most of these proteins were ECM or cytoskeletal components (Fig 1, B) . Hierarchical clustering analyses and principal component analysis strongly suggest that severe disease in PAD patients may have a specific proteome, as illustrated in Fig 1, C-E. The identified proteins suggested an imbalance favoring degradation of ECM proteins. Because of histologic changes in collagen and proteomic differences in versican, we selected specific neoepitope fragments of proteins describing the turnover of the major components of vascular ECM: versican, type IV collagen, mimecan, and laminin. Degradation fragments of C-reactive protein and a-smooth muscle actin were also included to investigate the influence of the inflammatory and fibroblastic components, respectively (Supplementary Table II , online only).
The clinical characteristics and laboratory measurements confirmed that the cohort of patients used for these measurements is representative of the clinical spectrum of PAD patients seeking attention in our facilities. The high prevalence of cardiovascular risk factors (such as smoking habits) and other associated treatment (mainly statins) did not significantly affect disease severity, with the exception of a lower prevalence of diabetes in Fontaine I patients. Age was also significantly associated with disease severity (Table I ). The concentration of the selected neoepitope biomarkers in serum of PAD patients with different Fontaine stages is indicated in Table II . Initially, specific fragments of MMP-8-and MMP-12-mediated degradation of versican (VCANM), of MMP-9-mediated degradation of a5 chain of laminin (Lam-a5), and of MMP-12-mediated degradation of a1 chain of type IV collagen (C4M) could separate patients in different disease stages. This was further confirmed for VCANM and C4M by using random forest analyses, but Lam-a5 levels failed to discriminate patients with IC from those with CLI. Serum VCANM concentration decreased progressively and was correlated with clinical severity. The analysis of receiver operating characteristic curves displayed a high sensitivity and specificity to distinguish between patients classified as type I from those with type IV (Fig 2, A and B) . A similar discriminative value was obtained for C4M, but circulating levels were increased according to disease severity (Fig 2, C and D). The combination of both potential biomarkers provided specificity higher than 90% to discriminate between patients with mild IC and those with severe PAD (Fig 2, E) , and none of them were associated with age or diabetes, the main risk factors for our PAD population. However, the standard technique for PAD diagnosis, the ABI, showed the best discriminant capacity (Fig 2, F) .
DISCUSSION
The clinical and prognostic relevance of atherosclerosis in the peripheral arteries of the lower limbs deserves further awareness by the medical community, but LEAD remains underdiagnosed and undertreated. 20 The relevance of risk factors, the role of drug prevention, and the causes of differential progression in noncoronary atherosclerosis have been scarcely investigated. 21 Organization models focused on a broad cardiovascular concept are currently an unmet need, which is hampered by the lack of biomarkers able to detect the asymptomatic stages and to predict or to monitor disease progression. Our findings confirm that atherosclerosis of the lower extremities may be a model to study arterial remodeling. In limb arteries, the lumen loss is not due to neointima formation but to an excessive reparative response, which includes factors favoring ECM degradation. 22 The specific proteome we have described of severe atherosclerotic lesions in peripheral arteries indicates that some proteins are overexpressed. For example, a 2 -macroglobulin and carboxypeptidase B2 contribute to the differences observed between diseased and control arteries. a 2 -Macroglobulin has recently been associated with plaque vulnerability in carotid arteries using a similar iTRAQ-based analysis, 23 and carboxypeptidase B2 may be a potential indicator of a high risk of premature PAD. 24 Conversely, other proteins were significantly decreased in diseased arteries compared with controls and are mostly related to tissue modeling and remodeling. Among them, low levels of lactadherin may indicate poor adhesion of smooth muscle cells to elastin fibers.
25
Decreased levels of structural proteins, which include versican, laminin, and mimecan, are highly influenced by MMP activity. These proteins also have defined roles in the maintenance of normal cardiovascular function and migration of smooth muscle cells. [26] [27] [28] [29] Taken together, our results indicate the coexistence of multiple mechanisms acting simultaneously in response to atherosclerotic injury. The results also highlight the central role of connective tissue turnover in the structural and signaling properties of arterial cells in LEAD. 14 With the rationale that measuring specific neoepitopes reflecting ECM turnover in the blood of our patients might contribute to the search for biomarkers of disease activity, we tested selected variables for evaluation. [30] [31] [32] [33] Among these circulating neoepitopes, those generated from a-smooth muscle actin and laminin a5 showed some potential by correlating with individual clinical end points (Supplementary Table II, online only; Table I ), but our focus was on clinically separating patients with mild PAD (IC, Fontaine I-II) from those with severe PAD (CLI, Fontaine III-IV). Serum concentrations of versican (VCANM) and type IV collagen (C4M) degradation products were the most accurate separators. The activities of MMPs in fibroproliferative diseases are well tool for tracking atherosclerosis progression in the arterial wall tissue. Type IV collagen is a major component of basement membranes, 38 and these results are consistent with the observed alterations of the collagen network morphology apparently leading to deterioration of mechanical properties and propensity to rupture of the arterial wall. ABI showed the best discriminant capacity, but ECM markers provide complementary information to patients who are referred because of clinically suspected arterial disease, especially those with normal resting ABI. 39 To our knowledge, this is the first study identifying neoepitope biomarkers of ECM remodeling as biomarkers for disease activity in LEAD. These measurements correlate with clinical end points and apparently provide clinically relevant information on processes reflecting atherosclerosis progression in lower extremity arteries. Exploring and re-evaluating the relationship between measurable biologic processes and clinical outcomes is crucial for deepening our knowledge on the role of arterial pathophysiologic changes in response to atherosclerosis. Whether these data reflect causality or document ECM changes during disease progression remains unknown.
The next level of evaluation needs other designs to ascertain predictive power in patients with asymptomatic PAD, and surrogate marker-defined efficacy calls for phase 4 follow-up studies. In this exploratory study, main limitations are the type of study and the common association of the disease with other cardiovascular disturbances. Future studies in prospective cohorts should consider the inclusion of women as well as the exclusion of coincident cardiovascular diseases and the usefulness of these markers after surgery. We envision that our proposed, laboratory-measured biomarkers may have the potential to speed drug development and to improve clinical awareness of the disease in primary care.
CONCLUSIONS
Severe lesions in PAD have a specific proteome compared with healthy arteries of age-matched controls. Our proteomics analysis indicates that inflammation and ECM turnover (ie, vascular remodeling) are the most quantitatively important processes in diseased arteries. We propose versican and type IV collagen degradation products as potential laboratory-measured biomarkers of disease activity.
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SUPPLEMENTARY METHODS (online only).
Tissue collection, handling, and preservation We have limited our study to samples obtained from superficial femoral arteries with occlusion or severe stenosis. This is because there are significant differences between femoral, superficial femoral, and tibial vessels in terms of size and pathophysiologic and morphologic features of the plaque. Portions of the artery included the entire artery wall. In diseased arteries, timing, handling, and preservation conditions were the same in all cases per protocol. Differences in timing were unavoidable for control arteries obtained in road accident victims. Age and anatomic area were especially considered. Handling and preservation of arterial specimens of deceased individuals and participants were kept to a minimum with immediate freezing and maintenance at À80 C until the analyses.
Proteomics protocol
Tissue processing and protein preparation. Stored frozen pieces of arteries were cut in 100-mg pieces and placed into tubes with 8 mg of type 1 collagenase in 2 mL of tris-CaCl 2 buffer. Samples were incubated at 37 C for 30 minutes with shaking. They were then centrifuged at 5000 rpm at 4 C, supernatants were stored at À80 C, and pellets were resuspended in 1.5 mL of urea lysis buffer þ0.1% sodium dodecyl sulfate. Samples were homogenized using Precellys 24 (Bertin Technologies, Montigny-le-Bretonneux, France) at 5000 rpm for 10 seconds. Immediately, they were sonicated and then centrifuged again at 2100 rpm for 10 minutes at 4 C.
Pellets were discarded, supernatants were transferred into new tubes and centrifuged at 14,000 rpm for 1 hour at 4 C, and proteins were precipitated with trichloroacetic acid. Samples were placed at 4 C for 24 hours and then centrifuged at 5000 rpm for 10 minutes at 4 C.
Supernatants were rejected and pellets resuspended in 1 mL of cold acetone. Samples were again centrifuged at 5000 rpm for 10 minutes at 4 C, supernatants were rejected, and pellets were resuspended in 0.5 M triethylammonium bicarbonate (TEAB) at pH 8.5. Protein quantification was performed, and samples were stored at À80 C.
Protein digestion and validation. After being vacuum dried, samples were resuspended in 0.5 M TEAB at pH 7, and 2% sodium dodecyl sulfate was added to denature proteins. Samples were reduced using 5 mM tris(2-carboxyethyl)phosphine in 50 mM TEAB at pH 7.9 for 1 hour at 60 C and then alkylated with 3.65 mM iodoacetamide during 30 minutes at room temperature in the dark. For the digestion, samples were incubated with 1 mg/mL sequencing-grade trypsin in 500 mM TEAB at pH 7.9 overnight at 37 C. Digestions were checked by analyzing a small aliquot using matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MS) or nano-liquid chromatography. Peptides were separated onto a C18 reversed phase nanocolumn (75-mm inner diameter [ID], 15-cm length, 3-mm particle diameter; Nikkyo Technos Co LTD, Tokyo, Japan) coupled with a trap nano-column (100-mm ID, 2-cm length, 5-mm particle diameter; Thermo Fisher Scientific, San Jose, Calif). Digested samples were analyzed by injecting an 18-mL sample, using a continuous acetonitrile gradient of 0% to 35% in 13 minutes, 35% to 80% in 7 minutes, and 80% to 100% in 5 minutes. In all the analysis, a flow rate of 300 nL/min was used to elute peptides for real-time ionization and peptide fragmentation on an LTQ Orbitrap Velos Pro mass spectrometer (Thermo Fisher). An enhanced Fourier transform (FT)-resolution spectrum (resolution ¼ 30,000 full half-maximum width [FHMW]) followed by data-dependent tandem MS (MS/MS) scan (R ¼ 15,000 FHMW) from most intense 10 parent ions with a charge state rejection of 1 was analyzed along the chromatographic run. The MS/MS scan was acquired in the FT analyzer using a higher energy collision dissociation collision cell with a normalized collision energy of 45 and dynamic exclusion of 0.5 minute.
Isobaric tag for relative and absolute quantitation (iTRAQ) labeling. iTRAQ 8-plex labeling reagents (SCIEX, Madrid, Spain) were added to samples according to the manufacturer's instructions and incubated at room temperature for 2 hours. Quantification results are expressed as ratios of the different labeling tags vs a control tag, and these ratios were used for statistical purposes.
Labeled samples were purified using an SCX column (Strata SCX 55 mm, 70Å; Phenomenex, Torrance, Calif).
Then, they were desalted and concentrated through a C18 Sep-Pak column (Waters, Bedford, Mass). Eluted peptides were dried and resuspended in 0.1% (v/v) formic acid for nano-liquid chromatography-MS/MS detection. Labeled iTRAQ peptides were separated onto a C18 reversed phase nanocolumn (75-mm ID, 15-cm length, 3-mm particle diameter; Nikkyo Technos Co LTD) coupled to a trap nanocolumn (100-mm ID, 2-cm length, 5-mm particle diameter; Thermo Fisher Scientific). All samples were analyzed in triplicate. For each analysis, 2 mg of sample was injected using a continuous acetonitrile gradient consisting of 0% to 5% B in 4 minutes, 5% to 15% B in 60 minutes, 15% to 35% B in 60 minutes, and 35% to 95% B in 10 minutes, which was maintained for 20 minutes (A ¼ water, 0.1% formic acid; B ¼ acetonitrile, 0.1% formic acid). In all the analysis, a flow rate of 300 nL/min was used to elute peptides for real-time ionization and peptide fragmentation on an LTQ ObritrapVelo sPro mass spectrometer (Thermo Fisher). An enhanced FTresolution spectrum (resolution ¼ 30,000 FHMW) followed by data-dependent MS/MS scan (R ¼ 15,000 FHMW) from most intense parent ions was analyzed throughout the chromatographic run. The MS/MS scan was acquired in the FT analyzer using a higher energy collision dissociation collision cell with normalized collision energy of 45%, a precursor mass window selection of 2 m/z, a charge state rejection of þ1, and a dynamic exclusion of 0.5 minute.
Protein identification analysis. Tandem mass spectra were extracted and charge state deconvoluted by Proteome Discoverer version 1.4.0.288 (Thermo Fisher Scientific). All MS and MS/MS samples were analyzed using Mascot (version 2.4.1.0; Thermo Fisher Scientific). Mascot was set up to search SwissProt_2012_03.fasta database (535248 entries), restricting for human taxonomy (26944 sequences) and assuming trypsin digestion. Two missed cleavages were allowed, and an error of 0.02 Da for fragment ion mass and 10.0 ppm for a parent ion were allowed. Oxidation of methionine, acetylation of Ntermini, and iTRAQ 8-plex were specified as variable modifications, whereas carbamidomethylation of cysteine was set as static modification. The false discovery rate and protein probabilities were calculated by Target Decoy PSM Validator working between 0.01 and 0.05 for strict and relaxed, respectively. For proteins identified with only one peptide, visual verification of fragmentation spectra was done.
Quantitative proteome analysis. In tandem MS mode, which isolates and fragments peptides, each tag generates a unique reporter ion used for a relative quantification. Protein quantification compares the peak intensity of the reporter ions in the MS/MS spectra to assess the relative abundance of the peptides and the proteins from which they are derived. The quantification method allows normalization with filters to measure the abundance of proteins in the sample using unique peptides of each protein.
Enzyme-linked immunosorbent assay protocol. The enzyme-linked immunosorbent assays were technically validated according to the Nordic Bioscience standard operating procedures. Linearity, lower limit of detection, intravariation and intervariation, spiking recovery, and assay stability were assessed. Protocols and buffers differ among assays. In general, a 96-well streptavidin precoated plate was coated with the selected biotinylated synthetic peptide dissolved in specific buffer and incubated. The peptide calibrator or sample was added to appropriate wells, followed by the horseradish peroxidase-conjugated monoclonal antibody, and again incubated. Finally, 3,3 0 ,5,5 0 -tetramethylbenzidine developer (cat.438OH; Kem-En-Tec, Taastrup, Denmark) was added, and the plate was incubated in the dark. All these incubation steps included shaking. After each incubation step, the plates were washed in washing buffer. The reaction was stopped by adding stopping solution (0.1 M H 2 SO 4 ) and measured at 450 to 650 nm. A standard calibration curve was also plotted. Supplementary Fig (online only) . Representative histologic findings in peripheral arteries from control group and peripheral artery disease (PAD) patients (magnification Â200). Hematoxylin and eosin (A), Masson trichrome (B), and sirius red (C) stains were used for assessment. The tunica intima was disorganized and thicker, and the presence of lipid vacuoles and cholesterol crystals and other histologic features were consistent with the higher (P < .0001) intima-media ratio observed in PAD patients (median, 
